[185]
As of December 1985, the inventors had tested levofloxacin, obtained data establishing the beneficial properties, and determined its absolute configuration to be "S". (Hayakawa Affidavit at paras. 39, 55-56, 59 and Ex. BB, at DAI-0024054, AR, v. 4, Tab 6, pp. 719, 723-725 and AR, v. 5, Tab 7, p. 1324.)